IDYA — Ideaya Biosciences Income Statement
0.000.00%
Last trade - 00:00- $2.56bn
- $1.89bn
- $7.00m
- 43
- 12
- 68
- 35
Annual income statement for Ideaya Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 19.5 | 27.9 | 50.9 | 23.4 | 7 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 54.9 | 78.2 | 113 | 158 | 334 |
| Operating Profit | -35.3 | -50.3 | -62.5 | -134 | -327 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -34.5 | -49.8 | -58.7 | -113 | -274 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -34.5 | -49.8 | -58.7 | -113 | -274 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -34.5 | -49.8 | -58.7 | -113 | -274 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -34.5 | -49.8 | -58.7 | -113 | -274 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.4 | -1.41 | -1.42 | -1.96 | -3.36 |